Who makes Aspirin enteric coated pellests 100mg?

Aspirin enteric coated pellests 100mg is developed by Boryung Pharmaceutical Co., Ltd.

What development phase is Aspirin enteric coated pellests 100mg in?

Aspirin enteric coated pellests 100mg is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Aspirin enteric coated pellests 100mg

Boryung Pharmaceutical Co., Ltd · FDA-approved active Small molecule Quality 2/100

Aspirin enteric coated pellets 100mg, marketed by Boryung Pharmaceutical Co., Ltd., holds a established position in the pharmaceutical market. The key composition patent expiring in 2028 provides a significant period of exclusivity, enhancing the drug's competitive advantage. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	Aspirin enteric coated pellests 100mg
Sponsor	Boryung Pharmaceutical Co., Ltd
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-controlled Hypertensive Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aspirin enteric coated pellests 100mg CI brief — competitive landscape report
Aspirin enteric coated pellests 100mg updates RSS · CI watch RSS
Boryung Pharmaceutical Co., Ltd portfolio CI